#61
|
||||
|
||||
Öèòàòà:
Öèòàòà:
|
#62
|
||||
|
||||
Updated review of the global carotid artery stent registry
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#63
|
||||
|
||||
Öèòàòà:
American Heart Association Departments Circulation. 91(2):566-579, January 15, 1995. Patients with either symptomatic or asymptomatic CAD in the presence of symptomatic coronary artery disease represent a difficult decision matrix. The options include operating on the carotid lesion first, with an increased risk of morbidity and mortality from myocardial infarction; operating on the coronary lesion first, with an increased risk of perioperative stroke; operating on both lesions during the same period of anesthesia; or operating on the coronary arteries alone. Of the 57 English-language papers on this topic, only 19 report on more than 50 patients. A meta-analysis of 56 reports reviewed three operative strategies: simultaneous carotid and coronary artery bypass grafting (CABG), carotid surgery followed by CABG, and CABG followed by carotid surgery. The meta-analysis indicates that the perioperative stroke rate was similar if carotid and coronary surgery were combined or if carotid surgery preceded coronary bypass grafting. The frequency of stroke was significantly greater if CABG preceded carotid surgery. However, the frequency of myocardial infarction (P=.01) and death (P=.02) were greater when carotid surgery preceded coronary bypass grafting Table 1 [58-121]. The optimal strategy for management of patients with combined coronary and carotid disease will be established only by a well-designed prospective randomized trial. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#64
|
||||
|
||||
Öèòàòà:
Òåì áîëåå â èõ àðñåíàëå äîñòàòî÷íî òåõíè÷åñêèõ ñðåäñòâ, ÷òîáû ñïðàâëÿòüñÿ ñ êðèòè÷åñêèì àòåðîñêëåðîçîì â ýòèõ áàññåéíàõ îäíîìîìåíòíî. Âñå ïîíÿòíî ïðî ðèñêè, íî î÷åíü ñîìíåâàþñü, ÷òî äàæå ïðè îòñðî÷åííîì øóíòèðîâàíèè òàêàÿ ðåâàñêóëÿðèçàöèÿ áóäåò cost-effective. Åñòü è ñîâåðøåííî äðóãîå ìíåíèå î÷åíü óâàæàåìûõ âðà÷åé èç ÖÝËÒà - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
|
#65
|
||||
|
||||
Öèòàòà:
Óâàæàåìûé GreyWolf, ÿ áóäó èñêðåííå áëàãîäàðåí çà òàêóþ ññûëêó. Íàèâíî âåðþ, ÷òî ñìîãó ÷òî-òî èçìåíèòü... Ïîêà æå ïîñòàðàþñü íàéòè óêàçàííóþ êíèãó ó íàøèõ íåéðîõèðóðãîâ. /ìûñëè âñëóõ/ß, áåçóñëîâíî, êðèòè÷åñêè ñëàá â âîïðîñàõ ïàòîìîðôîëîãèè èíñóëüòà, ïîýòîìó îñîáåííî ëþáîïûòíî, ïî÷åìó õèðóðãàì ðåêîìåíäóþò îïåðèðîâàòü ÷åðåç 2 íåäåëè, à ðåíòãåíîõèðóðãè æäóò äîëüøå. Îáâèíèòü â ýòîì íàøó ñóïðåññèþ àããðåãàöèè â ïåðâîì ïðèáëèæåíèè íå ïîëó÷àåòñÿ, âïðî÷åì, áóäó êîïàòü ãëóáæå Êñòàòè, â âûøåïðèâåäåííîé ñòàòüå êîñâåííûé îòâåò íà ìîé âîïðîñ - 3 íåäåëè (Ïðîòèâîïîêàçàíèÿ äëÿ êàðîòèäíîé àíãèîïëàñòèêè è ÊÑ (skipped) ðàííèé ïîñòèíñóëüòíûé ïåðèîä (äî 3 íåä äî ïðîöåäóðû) Äà, ÿ ñîãëàñåí, âñåãäà áûë â ýòîì óâåðåí. Íî äîïîëíèòåëüíûå î÷àãè íà ÌÐÒ îò÷åãî-òî âñå-òàêè ïîÿâëÿþòñÿ. Ìîæåò íå ñòîèò ñåáÿ íåäîîöåíèâàòü? Ó÷èòûâàÿ êàê âûãëÿäèò íåñòàáèëüíàÿ áëÿøêà èíòðàîïåðàöèîííî (ïðè èíòåðâåíöèè âñå ñìîòðèòñÿ áîëåå ñòàáèëüíî è êîíòðîëèðóåìî), - âïîëíå äîïóñêàþ, ÷òî ìåëêèå òðîìáû ìîæíî "ñêîâûðíóòü" è ïðîâîäíèêîì, è êîðçèíîé ôèëüòðà. Öèòàòà:
Ó ìåíÿ íå áûëî âîçìîæíîñòè ðàáîòàòü ñ "èíâàòåêîâñêîé ìîìîé" è àíàëîãàìè, íî, ïîäîçðåâàþ, åñëè áû îíà àäåêâàòíî ðåøàëà ïðîáëåìó äèñòàëüíîé ýìáîëèè, ïîáåäíîé ïëÿñêè ñ áóáíàìè ÿ áû âðÿä ëè íå çàìåòèë |
#66
|
|||
|
|||
Öèòàòà:
"In patients who require CABG, the risk of perioperative stroke is 4-fold higher in those with a past history of TIA or stroke and 10-fold higher in asymptomatic patients with carotid stenosis greater than 75% (212). Patients being considered for cardiac surgery should undergo a preoperative carotid duplex exam if any of the following are present: carotid bruit, age greater than 65 years, peripheral arterial disease, history of TIA or stroke, smoking, or left main coronary artery disease (24). Patients with a significant carotid stenosis are candidates for carotid revascularization. The timing and sequence of revascularization are influenced by the symptom status of the patient, the severity of disease, and the urgency of revascularization. CABG alone is reasonable for patients with asymptomatic carotid stenosis and critical left main disease, refractory acute coronary syndromes, or other indications for urgent CABG. In contrast, patients with recent (less than 2 weeks) TIA and 153 JACC Vol. 49, No. 1, 2007 Bates et al. January 2/9, 2007:126–70 ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Documentcarotid stenosis greater than 50% should be considered for urgent CEA, if CABG can be safely deferred for several days. The most recent guidelines (24) suggest that CEA is recommended before or concomitant to CABG in patients with symptomatic carotid stenosis greater than 50% or asymptomatic carotid stenosis greater than 80%. The risks of simultaneous CEA and CABG are not clearly higher than the risks of separate surgery and include death in 4.7%, stroke in 3.0%, and MI in 2.2% (173). If the procedures are to be staged, complication rates are lower when carotid revascularization precedes CABG. For patients who can defer CABG for 4 to 5 weeks, enrollment in one of the high-risk CAS registries is a potential option. Since CAS patients are treated with clopidogrel for one month, it is best to defer CABG for 5 weeks" |
#67
|
|||
|
|||
Öèòàòà:
Åñëè ïîêàçàíî ×ÊÂ, òî ñòåíòèðóåì ñîííóþ è êîðîíàðíóþ(ûå) àðòåðèè â îäíó ñåññèþ. Îäíîìó ìîëîäîìó ïàöèåíòó ñ òÿæåëîé ñòåíîêàðäèåé êàíäèäàòó íà ÀÊØ âûïîëíèëè îäíîìîìåíòíîå äâóõñòîðîííåå ñòåíòèðîâàíèå ñîííûõ (ïàöèåíò àñèìïòîìíûé), ïàöèåíò õîðîøî ïåðåíåñ ÀÊØ è äîñòàòî÷íî áûñòðî âûïèñàëñÿ. |
#68
|
||||
|
||||
Öèòàòà:
È âîïðîñ ê ñòîðîííèêàì ÊÝÝ - Êàê âû îòíîñèòåñü ê ïðîâåäåíèþ ïîäîáíûõ îïåðàöèé òîëüêî ïî äàííûì äóïëåêñà, êàê ýòî äåëàþò â ðÿäå êëèíèê ÐÔ (âîçâðàùàÿñü ê îáñóæäåíèþ â íà÷àëå òåìû ïî ðàñõîæäåíèþ äàííûõ ÓÇ-ìåòîäîâ ñ äàííûìè ÊÒ, ÌÐÒ è ñåëåêòèâíîé àíãèîãðàôèè). |
#69
|
||||
|
||||
Çäåñü ÐÑÏ âåðíóëñÿ ñ ×àðèíã Êðîññà. Îïóñêàÿ ññûëî÷íî-äîêàçàòåëüíóþ ÷àñòü, ñîîáùèë, ÷òî ñóäÿ ïî äèñêóññèè, ñòåíòèðîâàíèå ñîííûõ âñ¸ æå ïîõîðîíåíî.
__________________
Àáóãîâ Ñåðãåé Àëåêñàíäðîâè÷. Ðîññèéñêèé Íàó÷íûé Öåíòð Õèðóðãèè èì. àêàäåìèêà Á.Â. Ïåòðîâñêîãî. |
#70
|
||||
|
||||
Áóêâàëüíî ñåãîäíÿ ÷èòàë Àìåðèêàíñêèé õèðóðãè÷åñêèé æóðíàë (11, 2009), öåëèêîì ïîñâÿùåííûé CAS.  ðåäàêòîðñêîé ñòàòüå áûëî óêàçàíî, ÷òî îäíîé èç ïðè÷èí òîãî, ÷òî ðåçóëüòàòû ïîñëåäíèõ èññëåäîâàíèé ïî "Ñòåíèðîâàíèå vs ýíäàðòåðýêòîìèÿ" áûëè íå â ïîëüçó ñòåíòèðîâàíèÿ ÿâëÿåòñÿ íåêà÷åñòâåííûé (íåêîððåêòíûé) îòáîð ïàöèåíòîâ äëÿ ñòåíòèðîâàíèÿ. Ïî ãàéäëàéíàì îáÿçàòåëüíî ïðîâåäåíèå ëèáî àíãèîãðàôèè èëè ÊÒ (ÌÐÒ) ñ êîíòðàñòèðîâàíèåì.  ÷àñòíîñòè, ýòî èìååò çíà÷åíèå äëÿ îöåíêè äóãè àîðòû, ñòåïåíè èçâèòîñòè àðòåðèé è äð.
|
#71
|
||||
|
||||
Öèòàòà:
/Õîòÿ è ïðè èõ íàëè÷èè âðÿä ëè ðåøèëñÿ áû íà òàêóþ ñëîæíîñî÷èíåííóþ èíòåðâåíöèîííóþ àãðåññèþ/ Ïðèÿòíî ñëûøàòü, ÷òî âñå ðàáîòàåò. Ïîäîçðåâàþ, ÷òî ðå÷ü î áëåñòÿùåì àíãèîãðàôè÷åñêîì ðåçóëüòàòå ïëàñòèêè. Ïðîñòèòå çà çàíóäñòâî, íî ðå÷ü øëà î äèñòàëüíûõ ìèêðîýìáîëèÿõ... Âû æå íå äåëàëè MRI â DWI-ðåæèìå äî è ïîñëå? P.S.: Òîæå íè ðàçó íå âèäåë ïîëíîñòüþ ðàçîáùåííûé êðóã, õîòÿ öåðåáðàëüíûå àíãèîãðàôèè äåëàþòñÿ íà ïîòîêå. Öèòàòà:
Ê ñ÷àñòüþ, ýòîò àðãóìåíò ïðèìåíèì ïî÷òè êî âñåì èññëåäîâàíèÿì, ðåçóëüòàò êîòîðûõ íàì íå íðàâèòñÿ |
#72
|
|||
|
|||
×óâñòâóþ ñåáÿ êàê ôóòáîëèñò èç âòîðîé ëèãè çàáèâøèé ãîë â âîðîòà Ñïàðòàêà (ïðè÷åì ñëó÷àéíî) Çà 2009 ãîä ñòåíòèðîâàëè îêîëî 50 áîëüíûõ, â ýòîì óæå 16 (ïðîöåäóðà íå òðåáóåò óìåíèé óðîâíÿ Ñåðãåé Àëåêñàíäðîâè÷à). Äóìàþ â ïðèíöèïå äåëèòü áîëüíûõ ñ ñîñóäèñòûìè õèðóðãàìè íåò íåîáõîäèìîñòè, ñòåíòèðóåì òåõ, êîãî òå â ïðèíöèïå íå âîçüìóò: ñ îêêëþçèåé êîíòðëàòåðàëüíîé ñòîðîíû, ñ èíñóëüòîì, èíôàðêòîì â àíàìíåçå è ò.ä. è ò.ä. Ó íàñ ïîä áîêîì îòäåëåíèå ÍÑÎ, âûáèðàé íå õî÷ó. ×òî êàñàåòñÿ ãèïîòîíèè è áðàäèêàðäèè â ïîñëåîïåðàöèîííîì ïåðèîäå, òî îí âîçíèêàåò ó íàñ òîëüêî åñëè íàñ íå óñòðàèâàåò îñòàòî÷íûé ñòåíîç è ïðèõîäèòüñÿ "äîäóâàòü". Ñ óâàæåíèåì ...
|
#73
|
||||
|
||||
Àÿç! Ðàä âèäåòü - äîáðî ïîæàëîâàòü. Ïðåäëàãàþ âûñêàçàòüñÿ íà òåìó: à âîîáùå ñîííûå ñòåíòèðîâàòü íàäî?
__________________
Àáóãîâ Ñåðãåé Àëåêñàíäðîâè÷. Ðîññèéñêèé Íàó÷íûé Öåíòð Õèðóðãèè èì. àêàäåìèêà Á.Â. Ïåòðîâñêîãî. |
#74
|
||||
|
||||
|
#75
|
||||
|
||||
Öèòàòà:
È âîîáùå, íàñêîëüêî êîððåêòíî ñðàâíèâàòü ñòåíòèðîâàíèå è ÊÝÝ "ëîá â ëîá"?  ëþáîì ñëó÷àå ó êàæäîãî ìåòîäà åñòü ÷åòêèå ðàìêè, âûõîä çà êîòîðûå è ïðèâåäåò ê äèñêðèìèíàöèè òîé èëè èíîé ìåòîäèêè... ýòî òî, ÷òî è íàçûâàåòñÿ îòáîðîì áîëüíûõ. À âñÿ äèñêóññèÿ, ïîñëå ïåðåïðî÷òåíèÿ, íàòàëêèâàåò íà âîïðîñ - ËÈÁÎ ÑÒÅÍÒÈÐÎÂÀÍÈÅ, ËÈÁÎ ÝÍÄÀÐÒÅÐÝÊÒÎÌÈß. |